JP2022535880A5 - - Google Patents

Info

Publication number
JP2022535880A5
JP2022535880A5 JP2021572340A JP2021572340A JP2022535880A5 JP 2022535880 A5 JP2022535880 A5 JP 2022535880A5 JP 2021572340 A JP2021572340 A JP 2021572340A JP 2021572340 A JP2021572340 A JP 2021572340A JP 2022535880 A5 JP2022535880 A5 JP 2022535880A5
Authority
JP
Japan
Application number
JP2021572340A
Other languages
Japanese (ja)
Other versions
JPWO2020244654A5 (https=
JP2022535880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/094824 external-priority patent/WO2020244654A1/en
Publication of JP2022535880A publication Critical patent/JP2022535880A/ja
Publication of JPWO2020244654A5 publication Critical patent/JPWO2020244654A5/ja
Publication of JP2022535880A5 publication Critical patent/JP2022535880A5/ja
Pending legal-status Critical Current

Links

JP2021572340A 2019-06-06 2020-06-08 c-MET阻害剤を使用して癌患者を処置するための方法 Pending JP2022535880A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2019090294 2019-06-06
CNPCT/CN2019/090294 2019-06-06
CN2019092706 2019-06-25
CNPCT/CN2019/092706 2019-06-25
CN2019109906 2019-10-08
CNPCT/CN2019/109906 2019-10-08
PCT/CN2020/094824 WO2020244654A1 (en) 2019-06-06 2020-06-08 Method for treating cancer patients using c-met inhibitor

Publications (3)

Publication Number Publication Date
JP2022535880A JP2022535880A (ja) 2022-08-10
JPWO2020244654A5 JPWO2020244654A5 (https=) 2023-06-15
JP2022535880A5 true JP2022535880A5 (https=) 2023-06-15

Family

ID=73653139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572340A Pending JP2022535880A (ja) 2019-06-06 2020-06-08 c-MET阻害剤を使用して癌患者を処置するための方法

Country Status (6)

Country Link
US (1) US20220252603A1 (https=)
EP (1) EP3980783A4 (https=)
JP (1) JP2022535880A (https=)
CN (1) CN114599978A (https=)
CA (1) CA3142642A1 (https=)
WO (1) WO2020244654A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112592976B (zh) * 2020-12-30 2021-09-21 深圳市海普洛斯生物科技有限公司 一种检测met基因扩增的方法及装置
MX2023012434A (es) * 2021-04-21 2024-02-08 Apollomics Inc Diagnostico y tratamiento de cancer usando inhibidor de c-met.
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113013A2 (en) * 2007-03-15 2008-09-18 University Of Chicago C-met mutations and uses thereof
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR20130103734A (ko) * 2010-08-31 2013-09-24 제넨테크, 인크. 바이오마커 및 치료 방법
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术(太仓)有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
CN106008339B (zh) * 2016-06-08 2018-09-07 上海准视生物科技有限公司 一种放射性c-met靶向亲和小分子化合物及其应用

Similar Documents

Publication Publication Date Title
BR102021012107A2 (https=)
CN306152648S (https=)
CN306005121S (https=)
CN305540769S (https=)
CN305541912S (https=)
CN305649652S (https=)
CN305650238S (https=)
CN305651081S (https=)
CN305652139S (https=)
CN305667235S (https=)
CN305667363S (https=)
CN305687932S (https=)
CN305712738S (https=)
CN305717979S (https=)
CN305730338S (https=)
CN305731015S (https=)
CN305747558S (https=)
CN305751205S (https=)
CN305751700S (https=)
CN305751861S (https=)
CN305752749S (https=)
CN305816545S (https=)
CN305817471S (https=)
CN305818070S (https=)
CN305818594S (https=)